Yang B, et al. - Among 120 retrospectively enrolled young patients with endometrial atypical hyperplasia (EAH) and 40 patients with early stage endometrial cancer (EEC, FIGO stage IA, without myometrial invasion) who wanted to preserve their fertility, researchers assessed the effectiveness of comprehensive hysteroscopic evaluation and lesion resection in combination with progestin therapy. Until achieving complete response (CR), all patients received constant oral progestin in combination with hysteroscopic evaluation every 3 months. CR was achieved by 148 patients (97.4%), disease progressed in 3 EAH and 1 EEC patients; 8 patients were still in treatment. For CR achievement, 6.7 ± 0.3 months (range, 1–18 months) was reported as the mean treatment duration. Lesion size ≤2 cm showed significant correlation with shorter treatment time to achieve CR, following adjusting for patient age, body mass index (BMI), history of pregnancy, and type of conservative therapies. Overall, indicated the efficacy as well as the safety of comprehensive hysteroscopic evaluation and lesion resection plus progestin therapy as a fertility sparing therapy for patients with EAH or EEC.